Vertex Pharmaceuticals Poised for Continued Growth Despite Market Turmoil
-
Vertex Pharmaceuticals is a top-performing growth stock that has outperformed the market in 2022. Its main revenue driver is its cystic fibrosis drug Trikafta.
-
Vertex aims to diversify beyond cystic fibrosis. Its sickle cell disease drug exa-cel could get FDA approval in December 2022.
-
Vertex has a strong pipeline with candidates for pain, kidney disease, and diabetes. This supports its future growth potential.
-
Despite a high P/E ratio, Vertex has a very low PEG ratio of 0.53, suggesting its growth is undervalued.
-
With its wide moat, focus on underserved diseases, and innovation, Vertex is poised to continue delivering market-beating returns.